Monopar Therapeutics (MNPR) Expected to Announce Earnings on Tuesday

Monopar Therapeutics (NASDAQ:MNPR) will likely be posting its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Monopar Therapeutics to post earnings of ($0.8975) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Monopar Therapeutics (NASDAQ:MNPR) last posted its quarterly earnings data on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10). On average, analysts expect Monopar Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Monopar Therapeutics Price Performance

MNPR stock traded down $1.45 during trading on Tuesday, hitting $53.20. The stock had a trading volume of 16,455 shares, compared to its average volume of 222,248. Monopar Therapeutics has a twelve month low of $28.40 and a twelve month high of $105.00. The stock has a market capitalization of $355.87 million, a P/E ratio of -29.28 and a beta of 1.49. The company’s 50-day moving average price is $55.75 and its two-hundred day moving average price is $66.95.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a report on Monday, March 30th. Wall Street Zen cut Monopar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Finally, BTIG Research reiterated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $107.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in shares of Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company’s stock worth $85,908,000 after purchasing an additional 30,042 shares during the last quarter. RA Capital Management L.P. boosted its holdings in shares of Monopar Therapeutics by 30.5% during the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after purchasing an additional 156,000 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Monopar Therapeutics by 79.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company’s stock worth $15,274,000 after purchasing an additional 103,909 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Monopar Therapeutics during the 3rd quarter worth approximately $18,904,000. Finally, Siren L.L.C. acquired a new position in shares of Monopar Therapeutics during the 4th quarter worth approximately $13,863,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.